Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 22.17% and Operating profit at -182.05% over the last 5 years
3
With a growth in Operating Profit of 7.98%, the company declared Very Positive results in Dec 25
4
Risky - Negative EBITDA
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 24,415 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.81
-133.50%
5.85
Revenue and Profits:
Net Sales:
228 Million
(Quarterly Results - Dec 2025)
Net Profit:
-434 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.45%
0%
3.45%
6 Months
-25.93%
0%
-25.93%
1 Year
-6.25%
0%
-6.25%
2 Years
-14.29%
0%
-14.29%
3 Years
-51.22%
0%
-51.22%
4 Years
-81.98%
0%
-81.98%
5 Years
-93.98%
0%
-93.98%
AnGes, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.17%
EBIT Growth (5y)
-182.05%
EBIT to Interest (avg)
-9,928.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
0.09
Tax Ratio
1.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.91
EV to EBIT
-2.50
EV to EBITDA
-3.70
EV to Capital Employed
28.46
EV to Sales
28.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1138.21%
ROE (Latest)
-239.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
228.00
231.20
-1.38%
Operating Profit (PBDIT) excl Other Income
-1,588.10
-1,129.30
-40.63%
Interest
0.00
0.00
Exceptional Items
107.70
0.00
Consolidate Net Profit
-434.40
-722.80
39.90%
Operating Profit Margin (Excl OI)
-7,030.20%
-4,941.00%
-208.92%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -1.38% vs -5.90% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 39.90% vs 73.41% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
874.10
643.60
35.81%
Operating Profit (PBDIT) excl Other Income
-5,091.60
-5,737.80
11.26%
Interest
0.00
0.00
Exceptional Items
107.70
-20,105.80
100.54%
Consolidate Net Profit
-5,123.30
-28,129.00
81.79%
Operating Profit Margin (Excl OI)
-5,886.40%
-14,153.10%
826.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 35.81% vs 320.65% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 81.79% vs -278.20% in Dec 2024
About AnGes, Inc. 
AnGes, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






